<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vtio</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник трансплантологии и искусственных органов</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Transplantology and Artificial Organs</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-1191</issn><publisher><publisher-name>Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15825/1995-1191-2020-4-20-26</article-id><article-id custom-type="elpub" pub-id-type="custom">vtio-1258</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Клиническая трансплантология</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Clinical Transplantology</subject></subj-group></article-categories><title-group><article-title>Диагностическое значение микроРНК-101 и микроРНК-27 при остром отторжении трансплантированного сердца</article-title><trans-title-group xml:lang="en"><trans-title>Diagnostic value of miRNA-101 and miRNA-27 in acute heart transplant rejection</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Великий</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Velikiy</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>123182, Москва, ул. Щукинская, д. 1</p><p>Тел. (499) 193-87-62</p></bio><bio xml:lang="en"><p>1, Shchukinskaya str., Moscow, 123182, Russian Federation</p><p>Phone: (499) 193-87-62 </p></bio><email xlink:type="simple">dim_vel@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гичкун</surname><given-names>О. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Gichkun</surname><given-names>O. E.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шарапченко</surname><given-names>С. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Sharapchenko</surname><given-names>S. O.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Можейко</surname><given-names>Н. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Mozheiko</surname><given-names>N. P.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Курабекова</surname><given-names>Р. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Kurabekova</surname><given-names>R. M.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шевченко</surname><given-names>О. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Shevchenko</surname><given-names>O. P.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Shumakov National Medical Research Center of Transplantology and Artificial Organs</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России;&#13;
ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Shumakov National Medical Research Center of Transplantology and Artificial Organs;&#13;
Sechenov University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>25</day><month>01</month><year>2021</year></pub-date><volume>22</volume><issue>4</issue><fpage>20</fpage><lpage>26</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Великий Д.А., Гичкун О.Е., Шарапченко С.О., Можейко Н.П., Курабекова Р.М., Шевченко О.П., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Великий Д.А., Гичкун О.Е., Шарапченко С.О., Можейко Н.П., Курабекова Р.М., Шевченко О.П.</copyright-holder><copyright-holder xml:lang="en">Velikiy D.A., Gichkun O.E., Sharapchenko S.O., Mozheiko N.P., Kurabekova R.M., Shevchenko O.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.transpl.ru/vtio/article/view/1258">https://journal.transpl.ru/vtio/article/view/1258</self-uri><abstract><sec><title>Цель</title><p>Цель: определить диагностическое значение уровня экспрессии микроРНК-101 и  микроРНК-27 в отношении острого отторжения трансплантата у реципиентов сердца. </p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование включены 46 реципиентов сердца, среди них мужчин – 36 (78,3%); средний возраст реципиентов составил 47,7 ± 10,8 (от 16 до 67) года. Уровень экспрессии микроРНК в плазме крови определялся методом  количественной полимеразной цепной реакции (ПЦР). Верификацию отторжения  трансплантата проводили на основании морфологического исследования образцов эндомиокардиальных биоптатов. </p></sec><sec><title>Результаты</title><p>Результаты. Уровни экспрессии микроРНК-101 и микроРНК-27 у реципиентов с острым отторжением трансплантата достоверно ниже по сравнению с реципиентами без отторжения (р = 0,04 и р = 0,03 соответственно). При уровне экспрессии микроРНК-101 ниже найденного порогового значения вероятность риска развития острого отторжения  трансплантата возрастает в 1,8 раза (RR = 1,8 [95% ДИ 1,13–3,01]). При уровне экспрессии микроРНК-27 ниже найденного порогового значения вероятность риска развития острого отторжения трансплантата возрастает в 1,9 раза (RR = 1,9 [95% ДИ 1,12–3,37]). Одновременное снижение показателей экспрессии микроРНК-101 и микроРНК-27 ниже найденных пороговых значений повышает вероятность риска развития острого отторжения трансплантата в 2,0 раза (RR = 2,0 [95% ДИ 1,16–3,36]).</p></sec><sec><title>Заключение</title><p>Заключение. Уровни экспрессии микроРНК-101 и микроРНК-27 обладают  диагностической значимостью в отношении острого отторжения трансплантата у реципиентов сердца. </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective: to determine the diagnostic value of miRNA-101 and miRNA-27 expression levels for acute hearttransplant rejection. </p></sec><sec><title>Materials and methods</title><p>Materials and methods. The study enrolled 46 heart recipients, among whom were 36 men (78.3%); the average age of recipients was 47.7 = 10.8 (16 to 67) years. Serum microRNA expression levels were measured via quantitative polymerase chain reaction (PCR). Graft rejection was verified through morphological analysis of endomyocardial biopsy specimens. </p></sec><sec><title>Results</title><p>Results. The expression levels of miRNA-101 and miRNA-27 in recipients with acute graft rejection are significantly lower than in recipients without rejection (p = 0.04 and p = 0.03, respectively). When the miRNA-101 expression level is below the determined threshold value, the risk  of developing acute graft rejection increases 1.8 times (RR = 1.8 [95% CI 1.13–3.01]). When the miRNA-27 expression level is below the determined threshold value, the risk of developing acute graft rejection increases 1.9 times (RR = 1.9 [95% CI 1.12–3.37]). Simultaneous decrease in the expression levels of miRNA-101 and miRNA-27 below the determined threshold values increases the likelihood of acute graft rejection by 2.0 times (RR = 2.0 [95% CI 1.16–3.36]). </p></sec><sec><title>Conclusion</title><p>Conclusion. The serum miRNA-101 and miRNA-27 expression levels are of diagnostic value for acute graft rejection in heart recipients. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>трансплантация сердца</kwd><kwd>микроРНК-101</kwd><kwd>микроРНК-27</kwd><kwd>острое отторжение</kwd><kwd>биомаркеры</kwd></kwd-group><kwd-group xml:lang="en"><kwd>heart transplantation</kwd><kwd>miRNA-101</kwd><kwd>miRNA-27</kwd><kwd>acute rejection</kwd><kwd>biomarkers</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Готье СВ, Шевченко АО, Попцов ВН. Пациент с трансплантированным сердцем: руководство для врачей по ведению пациентов, перенесших трансплантацию сердца. М.: Триада, 2014. 144.</mixed-citation><mixed-citation xml:lang="en">Gautier SV, Shevchenko AO, Popcov VN. Pacient s transplantirovannym serdcem: rukovodstvo dlya vrachej po vedeniyu pacientov, perenesshih transplantaciyu serdca. M.: Triada, 2014. 144.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Шевченко АО, Никитина ЕА, Колоскова НН, Шевченко ОП, Готье СВ. Контролируемая артериальная гипертензия и выживаемость без нежелательных событий у реципиентов сердца. Кардиоваскулярная терапия и профилактика. 2018; 17 (4): 4–11.</mixed-citation><mixed-citation xml:lang="en">Shevchenko AO, Nikitina EA, Koloskova NN, Shevchenko OP, Gautier SV. Kontroliruemaja arterial’naja gipertenzija i vyzhivaemost’ bez nezhelatel’nyh sobytij u recipientov serdca. Kardiovaskuljarnaja terapija i profilaktika. 2018; 17 (4): 4–11. [In Russ, English abstract].</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Stehlik J, Starling RC, Movsesian MA, Fang JC, Brown RN, Hess ML et al. Cardiac Transplant Research Database Group. Utility of long-term surveillance endomyocardial biopsy: a multi-institutional analysis. J Heart Lung Transplant. 2006; 25 (12): 1402–1409.</mixed-citation><mixed-citation xml:lang="en">Stehlik J, Starling RC, Movsesian MA, Fang JC, Brown RN, Hess ML et al. Cardiac Transplant Research Database Group. Utility of long-term surveillance endomyocardial biopsy: a multi-institutional analysis. J Heart Lung Transplant. 2006; 25 (12): 1402–1409.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Crespo-Leiro MG, Barge-Caballero G, Couto-Mallon D. Noninvasive monitoring of acute and chronic rejection in heart transplantation. Curr Opin Cardiol. 2017; 32 (3): 308–315.</mixed-citation><mixed-citation xml:lang="en">Crespo-Leiro MG, Barge-Caballero G, Couto-Mallon D. Noninvasive monitoring of acute and chronic rejection in heart transplantation. Curr Opin Cardiol. 2017; 32 (3): 308–315.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Шумаков ВИ, Шевченко ОП, Хубутия МШ, Орлова ОВ, Казаков ЭН, Кормер АЯ, Олефиренко ГА. Васкулопатия трансплантированного сердца: синергизм провоспалительных, проатерогенных факторов и вирусной инфекции. Вестник Российской академии медицинских наук. 2006; 11: 8–14.</mixed-citation><mixed-citation xml:lang="en">Shumakov VI, Shevchenko OP, Hubutiya MSh, Orlova OV, Kazakov EN, Kormer AYa, Olefirenko GA. Vaskulopatiya transplantirovannogo serdca: sinergizm provospalitel’nyh, proaterogennyh faktorov i virusnoj infekcii. Vestnik Rossijskoj akademii medicinskih nauk. 2006; 11: 8–14.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Savic-Radojevic A, Pljesa-Ercegovac M, Matic M et al. Novel biomarkers of heart failure. Advances In Clinical Chemistry. 2017; 79: 93–152.</mixed-citation><mixed-citation xml:lang="en">Savic-Radojevic A, Pljesa-Ercegovac M, Matic M et al. Novel biomarkers of heart failure. Advances In Clinical Chemistry. 2017; 79: 93–152.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kransdorf EP, Kobashigawa JA. Novel molecular approaches to the detection of heart transplant rejection. Per Med. 2017 Jul; 14 (4): 293–297.</mixed-citation><mixed-citation xml:lang="en">Kransdorf EP, Kobashigawa JA. Novel molecular approaches to the detection of heart transplant rejection. Per Med. 2017 Jul; 14 (4): 293–297.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">van Gelder T. Biomarkers in solid organ transplantation. Br J Clin Pharmacol. 2017 Dec; 83 (12): 2602–2604.</mixed-citation><mixed-citation xml:lang="en">van Gelder T. Biomarkers in solid organ transplantation. Br J Clin Pharmacol. 2017 Dec; 83 (12): 2602–2604.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Starling RC, Stehlik J, Baran DA et al. Multicenter analysis of immune biomarkers and heart transplant outcomes: results of the clinical trials in organ transplantation-05 study. American Journal of Transplantation. 2016; 16: 121–136.</mixed-citation><mixed-citation xml:lang="en">Starling RC, Stehlik J, Baran DA et al. Multicenter analysis of immune biomarkers and heart transplant outcomes: results of the clinical trials in organ transplantation-05 study. American Journal of Transplantation. 2016; 16: 121–136.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Di Francesco A, Fedrigo M, Santovito D, Natarelli L, Castellani C, De Pascale F et al. MicroRNA signatures in cardiac biopsies and detection of allograft rejection. J Heart Lung Transplant. 2018 Nov; 37 (11): 1329–1340.</mixed-citation><mixed-citation xml:lang="en">Di Francesco A, Fedrigo M, Santovito D, Natarelli L, Castellani C, De Pascale F et al. MicroRNA signatures in cardiac biopsies and detection of allograft rejection. J Heart Lung Transplant. 2018 Nov; 37 (11): 1329–1340.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Shah P, Bristow MR, Port JD. MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential. Curr Heart Fail Rep. 2017 Dec; 14 (6): 454–464.</mixed-citation><mixed-citation xml:lang="en">Shah P, Bristow MR, Port JD. MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential. Curr Heart Fail Rep. 2017 Dec; 14 (6): 454–464.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Khush K, Zarafshar S. Molecular Diagnostic Testing in Cardiac Transplantation. Curr Cardiol Rep. 2017 Oct 13; 19 (11): 118.</mixed-citation><mixed-citation xml:lang="en">Khush K, Zarafshar S. Molecular Diagnostic Testing in Cardiac Transplantation. Curr Cardiol Rep. 2017 Oct 13; 19 (11): 118.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Великий ДА, Гичкун ОЕ, Шарапченко СО, Шевченко ОП, Шевченко АО. Уровень экспрессии микроРНК в ранние и отдаленные сроки после трансплантации у реципиентов сердца. Вестник трансплантологии и искусственных органов. 2020; 22 (1): 26–34.</mixed-citation><mixed-citation xml:lang="en">Velikiy DA, Gichkun OE, Sharapchenko SO, Shevchenko OP, Shevchenko AO. Uroven’ ekspressii mikroRNK v rannie i otdalennye sroki posle transplantacii u recipientov serdca. Vestnik transplantologii i iskusstvennyh organov. 2020; 22 (1): 26–34.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001 Dec; 25 (4): 402–408.</mixed-citation><mixed-citation xml:lang="en">Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001 Dec; 25 (4): 402–408.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Li X, Zhang S, Wa M, Liu Z, Hu S. microRNA-101 Protects Against Cardiac Remodeling Following Myocardial Infarction via Downregulation of Runt-Related Transcription Factor 1. J Am Heart Assoc. 2019 Dec 3; 8 (23): e013112.</mixed-citation><mixed-citation xml:lang="en">Li X, Zhang S, Wa M, Liu Z, Hu S. microRNA-101 Protects Against Cardiac Remodeling Following Myocardial Infarction via Downregulation of Runt-Related Transcription Factor 1. J Am Heart Assoc. 2019 Dec 3; 8 (23): e013112.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Huang C, Xiao X, Yang Y, Mishra A, Liang Y, Zeng X et al. MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation. J Biol Chem. 2017 Oct 6; 292 (40): 16420–16439.</mixed-citation><mixed-citation xml:lang="en">Huang C, Xiao X, Yang Y, Mishra A, Liang Y, Zeng X et al. MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation. J Biol Chem. 2017 Oct 6; 292 (40): 16420–16439.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Meroni M, Longo M, Erconi V, Valenti L, Gatti S, Fracanzani AL, Dongiovanni P. Mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance. Nutrients. 2019 Oct 29; 11 (11): 2597.</mixed-citation><mixed-citation xml:lang="en">Meroni M, Longo M, Erconi V, Valenti L, Gatti S, Fracanzani AL, Dongiovanni P. Mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance. Nutrients. 2019 Oct 29; 11 (11): 2597.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang XL, An BF, Zhang GC. MiR-27 alleviates myocardial cell damage induced by hypoxia/reoxygenation via targeting TGFBR1 and inhibiting NF-κB pathway. Kaohsiung J Med Sci. 2019 Oct; 35 (10): 607–614.</mixed-citation><mixed-citation xml:lang="en">Zhang XL, An BF, Zhang GC. MiR-27 alleviates myocardial cell damage induced by hypoxia/reoxygenation via targeting TGFBR1 and inhibiting NF-κB pathway. Kaohsiung J Med Sci. 2019 Oct; 35 (10): 607–614.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y, Cai H, Li H, Gao Z, Song K. Atrial overexpression of microRNA-27b attenuates angiotensin II-induced atrial fibrosis and fibrillation by targeting ALK5. Hum Cell. 2018 Jul; 31 (3): 251–260.</mixed-citation><mixed-citation xml:lang="en">Wang Y, Cai H, Li H, Gao Z, Song K. Atrial overexpression of microRNA-27b attenuates angiotensin II-induced atrial fibrosis and fibrillation by targeting ALK5. Hum Cell. 2018 Jul; 31 (3): 251–260.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Hughes G. Youden’s Index and the Weight of Evidence Revisited. Methods Inf Med. 2015; 54 (6): 576–577.</mixed-citation><mixed-citation xml:lang="en">Hughes G. Youden’s Index and the Weight of Evidence Revisited. Methods Inf Med. 2015; 54 (6): 576–577.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
